Sopharma Trading AD Valuation

Is SFT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SFT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SFT (BGN5.75) is trading below our estimate of fair value (BGN19.04)

Significantly Below Fair Value: SFT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SFT?

Key metric: As SFT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SFT. This is calculated by dividing SFT's market cap by their current earnings.
What is SFT's PE Ratio?
PE Ratio	5.7x
Earnings	лв34.72m
Market Cap	лв197.09m

SFT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	6.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does SFT's PE Ratio compare to its peers?

The above table shows the PE ratio for SFT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	12.6x
7600 Japan Medical Dynamic Marketing	11.6x	14.9%	JP¥16.3b
3154 Medius Holdings	15.7x	n/a	JP¥17.4b
3055 Hokuyaku Takeyama HoldingsInc	7.6x	n/a	JP¥17.8b
9600 Qomel	15.6x	n/a	ر.س364.0m
SFT Sopharma Trading AD	5.7x	n/a	лв197.1m

Price-To-Earnings vs Peers: SFT is good value based on its Price-To-Earnings Ratio (5.7x) compared to the peer average (12.7x).

Price to Earnings Ratio vs Industry

How does SFT's PE Ratio compare vs other companies in the European Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: SFT is good value based on its Price-To-Earnings Ratio (5.7x) compared to the European Healthcare industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is SFT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SFT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	5.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SFT's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Siemens Healthineers

€54.9b

Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.

SHL

€48.44

n/a

Carl Zeiss Meditec

€5.1b

Operates as a medical technology company in Germany, rest of Europe, North America, and Asia.

AFX

€57.45

0.3%

-33.9%

Etropal AD

лв21.0m

Engages in the research, development, and manufacture of disposable medical devices for dialysis in Bulgaria.

ETR

лв4.20

2.4%

-12.5%